AIM ImmunoTech Completes First Dose in DURIPANC Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: AIM ImmunoTech announced that the final subject has received their first dose in the DURIPANC clinical trial, which evaluates the efficacy of its lead drug Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, marking a significant advancement in cancer treatment.
- Trial Design and Objectives: DURIPANC is an investigator-initiated exploratory Phase 2 study primarily assessing clinical benefit rate, while also analyzing overall survival and progression-free survival as secondary objectives, aiming to provide data support for a subsequent Phase 3 study.
- Data Analysis Timeline: With the final dosing completed, primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in the first quarter of 2027, while secondary endpoint analysis is projected to start in June 2027, indicating the company's clear planning for future research.
- Market Performance Overview: AIM's stock has traded between $0.21 and $19.73 over the past year, closing at $0.38, down 5.03% from the previous trading day, reflecting market caution regarding the company's clinical progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIM
Wall Street analysts forecast AIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.297
Low
22.00
Averages
22.00
High
22.00
Current: 0.297
Low
22.00
Averages
22.00
High
22.00
No data
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship product Ampligen is a double-stranded ribonucleic acid (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Alferon N Injection (Interferon alfa) is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. It is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferons. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIM ImmunoTech Completes First Dose in DURIPANC Trial
- Clinical Trial Progress: AIM ImmunoTech announced that the final subject has received their first dose in the DURIPANC clinical trial, which evaluates the efficacy of its lead drug Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, marking a significant advancement in cancer treatment.
- Trial Design and Objectives: DURIPANC is an investigator-initiated exploratory Phase 2 study primarily assessing clinical benefit rate, while also analyzing overall survival and progression-free survival as secondary objectives, aiming to provide data support for a subsequent Phase 3 study.
- Data Analysis Timeline: With the final dosing completed, primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in the first quarter of 2027, while secondary endpoint analysis is projected to start in June 2027, indicating the company's clear planning for future research.
- Market Performance Overview: AIM's stock has traded between $0.21 and $19.73 over the past year, closing at $0.38, down 5.03% from the previous trading day, reflecting market caution regarding the company's clinical progress.
See More
AIM ImmunoTech Launches DURIPANC Clinical Trial for Pancreatic Cancer
- Clinical Trial Progress: AIM ImmunoTech announced that the final subject in the DURIPANC clinical trial has received their first dose, with primary endpoint analysis expected to begin in December 2026 and topline results anticipated in Q1 2027, demonstrating the company's ongoing commitment to pancreatic cancer treatment.
- Primary Endpoint Definition: The primary endpoint of DURIPANC is the Clinical Benefit Rate (CBR), defined as the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks post-initiation of combination therapy, which will provide critical data for future treatment strategies.
- Survival Rate Analysis: Early data shows that patients with Neutrophil/Lymphocyte ratios below 4.5 had a progression-free survival (PFS) of 17.7 months compared to 8.6 months for historical controls, indicating a 9.1-month improvement and suggesting Ampligen's potential efficacy in specific patient subsets.
- Future Research Directions: AIM plans to leverage biomarker data generated from DURIPANC to design a Phase 3 clinical trial, focusing on identifying 'super-responder' patient subsets to enable more targeted and personalized treatment approaches, further advancing the company's strategic positioning in cancer therapy.
See More
AIM ImmunoTech Regains NYSE Compliance
- Compliance Restoration: AIM ImmunoTech announced that it has regained compliance with NYSE American, meeting the minimum stockholders' equity requirement, which ends its previous violation status and signifies improved stability in the capital markets.
- Financing Progress: By entering into an agreement with existing warrant holders, the company secured $3.5 million in financing in May 2026, demonstrating market confidence in its future development.
- Stock Issuance: In May and June 2026, the company issued over 10 million shares of common stock, raising approximately $6.2 million, which strengthens its capital base to support future business growth.
- Equity Improvement: Following these transactions, AIM's stockholders' equity exceeded the $6 million minimum requirement, further solidifying its listing status on the NYSE and enhancing investor confidence.
See More
AIM ImmunoTech Secures $2.65 Million Financing
- Financing Size: AIM ImmunoTech announced a registered direct offering of 2.55 million shares at $0.5189 per share, aiming for gross proceeds of approximately $2.65 million, yet the stock fell 19.5% to $0.43, indicating market caution regarding the offering.
- Use of Proceeds: The net proceeds from this offering will be allocated to manufacturing clinical drug supplies, ongoing clinical trial activities, planned Phase 3 trials, and working capital, reflecting the company's strategic focus on advancing its research and clinical initiatives.
- Warrant Issuance: The offering includes 2.55 million unregistered shares and Class J warrants to purchase up to 10.21 million shares at an exercise price of $0.5189, contingent on shareholder approval, highlighting the company's reliance on future shareholder support.
- Transaction Timeline: The offering is expected to close around June 10, 2026, demonstrating the company's strategic planning in capital operations despite facing stock price volatility challenges.
See More
AIM ImmunoTech Announces $2.65 Million Financing
- Financing Size: AIM ImmunoTech announced a registered direct offering and concurrent private placement to raise approximately $2.65 million, reflecting the company's active engagement in capital markets, with an expected closing date of June 10, 2026.
- Stock Issuance Details: The company will issue 2,554,119 shares of common stock at a price of $0.5189 per share, alongside an equal number of unregistered shares and Class J warrants to purchase up to 10,216,476 shares, enhancing the flexibility of its capital structure.
- Use of Proceeds: The net proceeds from this offering will be allocated for manufacturing clinical drug supplies, current and planned clinical trial activities, and working capital, indicating the company's proactive approach to R&D and market expansion.
- Compliance and Transparency: The offering is made in reliance on an exemption under Section 4(a)(2) of the Securities Act, ensuring compliance, while a prospectus supplement filed with the SEC provides transparent disclosures, thereby boosting investor confidence.
See More
AIM ImmunoTech Reports Positive Clinical Progress in Pancreatic Cancer Study
- Clinical Trial Progress: AIM ImmunoTech has enrolled the final patient in the DURIPANC study, with a planned evaluation of the Clinical Benefit Rate (CBR) in December 2026, which could provide new treatment options for pancreatic cancer patients through the combination of Ampligen and AstraZeneca's Imfinzi.
- Survival Data: In a 57-subject Named Patient Program, Ampligen as a monotherapy demonstrated a median survival of 19.7 months, extending overall survival by 8.6 months compared to standard care, highlighting its potential to improve patient outcomes and quality of life.
- Immune Marker Analysis: Among patients with Neutrophil/Lymphocyte ratios below 4.5 in the NPP study, the overall median survival reached 34.8 months, an improvement of 22.3 months over historical controls, further validating the clinical value of Ampligen.
- Future Development Plans: AIM is planning a Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor, aiming to demonstrate significant survival results, which could position AIM as a leader in pancreatic cancer research if successful.
See More
AIM ImmunoTech Completes First Dose in DURIPANC Trial
- Clinical Trial Progress: AIM ImmunoTech announced that the final subject has received their first dose in the DURIPANC clinical trial, which evaluates the efficacy of its lead drug Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, marking a significant advancement in cancer treatment.
- Trial Design and Objectives: DURIPANC is an investigator-initiated exploratory Phase 2 study primarily assessing clinical benefit rate, while also analyzing overall survival and progression-free survival as secondary objectives, aiming to provide data support for a subsequent Phase 3 study.
- Data Analysis Timeline: With the final dosing completed, primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in the first quarter of 2027, while secondary endpoint analysis is projected to start in June 2027, indicating the company's clear planning for future research.
- Market Performance Overview: AIM's stock has traded between $0.21 and $19.73 over the past year, closing at $0.38, down 5.03% from the previous trading day, reflecting market caution regarding the company's clinical progress.
See More
AIM ImmunoTech Launches DURIPANC Clinical Trial for Pancreatic Cancer
- Clinical Trial Progress: AIM ImmunoTech announced that the final subject in the DURIPANC clinical trial has received their first dose, with primary endpoint analysis expected to begin in December 2026 and topline results anticipated in Q1 2027, demonstrating the company's ongoing commitment to pancreatic cancer treatment.
- Primary Endpoint Definition: The primary endpoint of DURIPANC is the Clinical Benefit Rate (CBR), defined as the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks post-initiation of combination therapy, which will provide critical data for future treatment strategies.
- Survival Rate Analysis: Early data shows that patients with Neutrophil/Lymphocyte ratios below 4.5 had a progression-free survival (PFS) of 17.7 months compared to 8.6 months for historical controls, indicating a 9.1-month improvement and suggesting Ampligen's potential efficacy in specific patient subsets.
- Future Research Directions: AIM plans to leverage biomarker data generated from DURIPANC to design a Phase 3 clinical trial, focusing on identifying 'super-responder' patient subsets to enable more targeted and personalized treatment approaches, further advancing the company's strategic positioning in cancer therapy.
See More
AIM ImmunoTech Regains NYSE Compliance
- Compliance Restoration: AIM ImmunoTech announced that it has regained compliance with NYSE American, meeting the minimum stockholders' equity requirement, which ends its previous violation status and signifies improved stability in the capital markets.
- Financing Progress: By entering into an agreement with existing warrant holders, the company secured $3.5 million in financing in May 2026, demonstrating market confidence in its future development.
- Stock Issuance: In May and June 2026, the company issued over 10 million shares of common stock, raising approximately $6.2 million, which strengthens its capital base to support future business growth.
- Equity Improvement: Following these transactions, AIM's stockholders' equity exceeded the $6 million minimum requirement, further solidifying its listing status on the NYSE and enhancing investor confidence.
See More
AIM ImmunoTech Secures $2.65 Million Financing
- Financing Size: AIM ImmunoTech announced a registered direct offering of 2.55 million shares at $0.5189 per share, aiming for gross proceeds of approximately $2.65 million, yet the stock fell 19.5% to $0.43, indicating market caution regarding the offering.
- Use of Proceeds: The net proceeds from this offering will be allocated to manufacturing clinical drug supplies, ongoing clinical trial activities, planned Phase 3 trials, and working capital, reflecting the company's strategic focus on advancing its research and clinical initiatives.
- Warrant Issuance: The offering includes 2.55 million unregistered shares and Class J warrants to purchase up to 10.21 million shares at an exercise price of $0.5189, contingent on shareholder approval, highlighting the company's reliance on future shareholder support.
- Transaction Timeline: The offering is expected to close around June 10, 2026, demonstrating the company's strategic planning in capital operations despite facing stock price volatility challenges.
See More
AIM ImmunoTech Announces $2.65 Million Financing
- Financing Size: AIM ImmunoTech announced a registered direct offering and concurrent private placement to raise approximately $2.65 million, reflecting the company's active engagement in capital markets, with an expected closing date of June 10, 2026.
- Stock Issuance Details: The company will issue 2,554,119 shares of common stock at a price of $0.5189 per share, alongside an equal number of unregistered shares and Class J warrants to purchase up to 10,216,476 shares, enhancing the flexibility of its capital structure.
- Use of Proceeds: The net proceeds from this offering will be allocated for manufacturing clinical drug supplies, current and planned clinical trial activities, and working capital, indicating the company's proactive approach to R&D and market expansion.
- Compliance and Transparency: The offering is made in reliance on an exemption under Section 4(a)(2) of the Securities Act, ensuring compliance, while a prospectus supplement filed with the SEC provides transparent disclosures, thereby boosting investor confidence.
See More
AIM ImmunoTech Reports Positive Clinical Progress in Pancreatic Cancer Study
- Clinical Trial Progress: AIM ImmunoTech has enrolled the final patient in the DURIPANC study, with a planned evaluation of the Clinical Benefit Rate (CBR) in December 2026, which could provide new treatment options for pancreatic cancer patients through the combination of Ampligen and AstraZeneca's Imfinzi.
- Survival Data: In a 57-subject Named Patient Program, Ampligen as a monotherapy demonstrated a median survival of 19.7 months, extending overall survival by 8.6 months compared to standard care, highlighting its potential to improve patient outcomes and quality of life.
- Immune Marker Analysis: Among patients with Neutrophil/Lymphocyte ratios below 4.5 in the NPP study, the overall median survival reached 34.8 months, an improvement of 22.3 months over historical controls, further validating the clinical value of Ampligen.
- Future Development Plans: AIM is planning a Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor, aiming to demonstrate significant survival results, which could position AIM as a leader in pancreatic cancer research if successful.
See More
